Braveheart Bio
BRVEBraveheart Bio is a clinical-stage biopharmaceutical company dedicated to developing next-generation therapies for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.
Braveheart Bio has filed an S-1 registration statement with the SEC and is not yet trading. Financial statements will appear here once it begins reporting as a public company.
S-1 Filings
Registration statements filed with the SEC ahead of the planned listing
Competitors
By market cap
By revenue growth
Profile
Braveheart Bio is a clinical-stage biopharmaceutical company dedicated to developing next-generation therapies for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Its lead product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor designed to improve upon first-generation treatments by offering faster onset, deeper gradient response, and enhanced systolic safety. The company aims to reduce prescribing complexity and monitoring burdens for patients with both obstructive and non-obstructive forms of HCM.
Braveheart Bio is positioning itself as a developer of a potentially best-in-class cardiac myosin inhibitor with a differentiated safety and dosing profile compared to currently approved therapies.
Questions, answered.
- Who are Braveheart Bio's competitors?
- Braveheart Bio's key competitors include Cytokinetics, Tenaya Therapeutics, Inc., Edgewise Therapeutics, Inc., and others. These companies compete in similar markets and product categories.
- Who does Braveheart Bio partner with?
- Braveheart Bio's notable partners include Jiangsu Hengrui Pharmaceuticals Co., Ltd., Ollin Biosciences, Inc..
- Where is Braveheart Bio headquartered?
- Braveheart Bio is headquartered in United States of America.